A thiadiazole contains a basic skeleton represented by any of formulae (1), (2), and (3) in the molecule. ##STR00001##

A thiadiazole contains a basic skeleton represented by any of formulae (1), (2), and (3) in the molecule. ##STR00001##

There is provided compounds of formula I, wherein R1, R.sup.2a, R.sup.2b, R.sup.2c, X, Y, Z, R.sup.3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. ##STR00001##

There is provided compounds of formula I, wherein R1, R.sup.2a, R.sup.2b, R.sup.2c, X, Y, Z, R.sup.3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. ##STR00001##

Disclosed herein are compounds, compositions, and methods for inhibiting a histone methyltransferase. The compounds are verticillin derivatives that exhibit anti-proliferative activity against cancer cells. The compounds, compositions, and methods can be used to treat a subject with cancer.

The present disclosure provides compounds represented by Formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

The present disclosure provides compounds represented by Formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

Provided are a compound having an excellent semiconductor property and a method for producing the compound, an intermediate of the compound and a method for producing the intermediate, and an organic semiconductor material and an organic semiconductor device each obtained with use of the organic semiconductor material.

A compound represented by general formula (2):

##STR00001## where: A.sup.1 and A.sup.2 are CM.sup.1 or N, and M.sup.1 is H or the like; J.sup.1 and J.sup.2 are each independently a skeleton giving an electron donating property or an electron accepting property; and X.sup.1 and X.sup.2 are

##STR00002## where: M.sup.2 to M.sup.4 are H or the like, and M.sup.3 and M.sup.4 may be bonded to each other to form a ring.

Provided are a compound having an excellent semiconductor property and a method for producing the compound, an intermediate of the compound and a method for producing the intermediate, and an organic semiconductor material and an organic semiconductor device each obtained with use of the organic semiconductor material.

A compound represented by general formula (2):

##STR00001## where: A.sup.1 and A.sup.2 are CM.sup.1 or N, and M.sup.1 is H or the like; J.sup.1 and J.sup.2 are each independently a skeleton giving an electron donating property or an electron accepting property; and X.sup.1 and X.sup.2 are

##STR00002## where: M.sup.2 to M.sup.4 are H or the like, and M.sup.3 and M.sup.4 may be bonded to each other to form a ring.

A conjugation of a cytotoxic drug to a cell-binding molecule with a bis-linker (dual-linker) as shown in Formula (I). Bis-linkage methods of making a conjugate of a cytotoxic drug/molecule to a cell-binding agent in a specific manner are also described, as well as application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.

##STR00001##

wherein “” is an optional bond; X, Y, Z.sub.1, and Z.sub.2 are a functional group; m.sub.1 and n are a integer; L.sub.1 and L.sub.2 are a linker.